Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

Highest Quality | For Research Use Only

Buy B7-33 Peptide China

B7-33 peptide, or B-type Natriuretic Peptide (BNP) 7-33, is a truncated form of the B-type natriuretic peptide. This peptide has been a subject of significant interest in the field of cardiovascular research due to its cardio-protective properties. One of the most notable benefits of B7-33 is its ability to reduce myocardial infarct size. In addition to its cardioprotective effects, B7-33 also exhibits anti-fibrotic properties. It has been demonstrated to inhibit cardiac fibrosis, thereby improving cardiac function and potentially delaying the progression of heart failure.

Showing all 3 results

Potential Benefits of B7-33 Peptide

  • Cardiac Remodeling Attenuation: B7-33, a relaxin family peptide receptor 1 agonist, has been shown in studies to attenuate adverse cardiac remodeling associated with myocardial infarction (MI) in mice [1].
  • Functionally Selective Agonist of RXFP1: B7-33 is a functionally selective agonist of the G protein-coupled receptor, RXFP1. This functional selectivity could enhance the therapeutic potential of the peptide [2].
  • Stability Enhancement: B7-33 has been developed to have a higher affinity for its target, potentially providing stability and enhancing its therapeutic benefits [3].
  • Cardioprotective Effects: Research suggests the peptide maintains the cardioprotective effects of relaxin and has been shown to reduce left ventricular fibrosis more rapidly than other treatments [4].
  • Analgesic Effect: According to research, B7-33 has demonstrated an analgesic effect on persistent inflammatory pain in mice, offering potential benefits in pain management [5].
  • Antifibrotic Properties: Studies indicate B7-33 has been found to efficiently prevent or reverse organ fibrosis and dysfunction in rodent models of heart or lung disease, highlighting its potential as an anti-fibrotic agent [5].
  • Long-Acting Single-Chain Peptide Mimetic: B7-33 is a potent and long-acting single-chain peptide mimetic of human relaxin-2, which research suggests could be beneficial for cardiovascular diseases [6].
  • Potential Therapeutic Applications in Fibrosis: B7-33 was administered to mouse models with unilateral ureteral obstruction (UUO), and it showed promising results in managing fibrosis, which could expand its therapeutic applications [7].

References

[1] https://pubmed.ncbi.nlm.nih.gov/32295457/

[2] https://pubmed.ncbi.nlm.nih.gov/30155023/

[3] https://www.mdpi.com/ 1422-0067/24/16/12670

[4] https://www.sciencedirect.com/science/ article/pii/S0753332223001580

[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8213244/

[6] https://pubmed.ncbi.nlm.nih.gov/33555858/

[7] https://www.mdpi.com/ 2218-273X/13/8/1179

DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://china.direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.